A Novo Nordisk executive collapsed during President Trump’s announcement about lowering the cost of weight loss drugs like Wegovy and Ozempic. The executive received medical care and is now stable. The new deal between the White House and major drugmakers promises to slash prices and expand access to obesity medications.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.

Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as growth slows, but investors saw some cheer in a better-than-expected Medicare pricing deal that helped temper a share price slide.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the company to support the drug's approval in obesity, the study led to greater improvements in risk factors such as C-reactive protein and serum triglycerides.

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs that are already on the market.

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in its key drugs Ozempic and Wegovy, in a deal that some analysts said sounded less onerous than feared.

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.